vs
德康医疗（DXCM）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
德康医疗的季度营收约是利氏兄弟拍卖行的1.0倍（$1.3B vs $1.2B），德康医疗净利率更高（21.2% vs 9.1%，领先12.1%），德康医疗同比增速更快（21.6% vs 5.4%），过去两年德康医疗的营收复合增速更高（12.0% vs 6.3%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
DXCM vs RBA — 直观对比
营收规模更大
DXCM
是对方的1.0倍
$1.2B
营收增速更快
DXCM
高出16.2%
5.4%
净利率更高
DXCM
高出12.1%
9.1%
两年增速更快
DXCM
近两年复合增速
6.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.2B |
| 净利润 | $267.3M | $109.7M |
| 毛利率 | 62.9% | — |
| 营业利润率 | 25.6% | 14.7% |
| 净利率 | 21.2% | 9.1% |
| 营收同比 | 21.6% | 5.4% |
| 净利润同比 | 153.6% | -7.4% |
| 每股收益（稀释后） | $0.67 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMRBA
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.0B | $1.1B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $994.2M | $981.8M | ||
| Q2 24 | $1.0B | $1.1B |
净利润DXCMRBA
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $109.7M | ||
| Q3 25 | $283.8M | $95.5M | ||
| Q2 25 | $179.8M | $109.8M | ||
| Q1 25 | $105.4M | $113.4M | ||
| Q4 24 | $151.7M | $118.5M | ||
| Q3 24 | $134.6M | $76.1M | ||
| Q2 24 | $143.5M | $111.1M |
毛利率DXCMRBA
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
营业利润率DXCMRBA
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 14.7% | ||
| Q3 25 | 20.1% | 14.5% | ||
| Q2 25 | 18.4% | 15.9% | ||
| Q1 25 | 12.9% | 17.1% | ||
| Q4 24 | 17.0% | 18.1% | ||
| Q3 24 | 15.3% | 15.6% | ||
| Q2 24 | 15.7% | 18.4% |
净利率DXCMRBA
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 9.1% | ||
| Q3 25 | 23.5% | 8.7% | ||
| Q2 25 | 15.5% | 9.3% | ||
| Q1 25 | 10.2% | 10.2% | ||
| Q4 24 | 13.6% | 10.4% | ||
| Q3 24 | 13.5% | 7.8% | ||
| Q2 24 | 14.3% | 10.1% |
每股收益（稀释后）DXCMRBA
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.53 | ||
| Q3 25 | $0.70 | $0.43 | ||
| Q2 25 | $0.45 | $0.53 | ||
| Q1 25 | $0.27 | $0.55 | ||
| Q4 24 | $0.37 | $0.58 | ||
| Q3 24 | $0.34 | $0.36 | ||
| Q2 24 | $0.35 | $0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $531.5M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $2.7B | $5.6B |
| 总资产 | $6.3B | $12.1B |
| 负债/权益比越低杠杆越低 | — | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资DXCMRBA
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $531.5M | ||
| Q3 25 | $1.8B | $674.7M | ||
| Q2 25 | $1.2B | $710.2M | ||
| Q1 25 | $904.9M | $578.1M | ||
| Q4 24 | $606.1M | $533.9M | ||
| Q3 24 | $621.2M | $650.7M | ||
| Q2 24 | $939.2M | $599.5M |
总债务DXCMRBA
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.8B |
股东权益DXCMRBA
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $5.6B | ||
| Q3 25 | $2.7B | $5.5B | ||
| Q2 25 | $2.6B | $5.5B | ||
| Q1 25 | $2.3B | $5.3B | ||
| Q4 24 | $2.1B | $5.2B | ||
| Q3 24 | $2.0B | $5.2B | ||
| Q2 24 | $2.4B | $5.2B |
总资产DXCMRBA
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $12.1B | ||
| Q3 25 | $7.5B | $12.2B | ||
| Q2 25 | $7.3B | $12.2B | ||
| Q1 25 | $6.8B | $11.9B | ||
| Q4 24 | $6.5B | $11.8B | ||
| Q3 24 | $6.4B | $11.9B | ||
| Q2 24 | $6.8B | $12.1B |
负债/权益比DXCMRBA
| Q1 26 | — | — | ||
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $255.2M |
| 自由现金流经营现金流 - 资本支出 | — | $186.5M |
| 自由现金流率自由现金流/营收 | — | 15.5% |
| 资本支出强度资本支出/营收 | — | 5.7% |
| 现金转化率经营现金流/净利润 | — | 2.33× |
| 过去12个月自由现金流最近4个季度 | — | $719.2M |
8季度趋势，按日历期对齐
经营现金流DXCMRBA
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $255.2M | ||
| Q3 25 | $659.9M | $239.7M | ||
| Q2 25 | $303.0M | $326.5M | ||
| Q1 25 | $183.8M | $156.8M | ||
| Q4 24 | $301.4M | $184.5M | ||
| Q3 24 | $199.5M | $285.4M | ||
| Q2 24 | $279.4M | $337.3M |
自由现金流DXCMRBA
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | $186.5M | ||
| Q3 25 | $579.4M | $188.5M | ||
| Q2 25 | $208.9M | $241.7M | ||
| Q1 25 | $96.8M | $102.5M | ||
| Q4 24 | $176.8M | $127.9M | ||
| Q3 24 | $88.3M | $248.5M | ||
| Q2 24 | $213.3M | $308.6M |
自由现金流率DXCMRBA
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 15.5% | ||
| Q3 25 | 47.9% | 17.3% | ||
| Q2 25 | 18.1% | 20.4% | ||
| Q1 25 | 9.3% | 9.2% | ||
| Q4 24 | 15.9% | 11.2% | ||
| Q3 24 | 8.9% | 25.3% | ||
| Q2 24 | 21.2% | 28.2% |
资本支出强度DXCMRBA
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | 5.7% | ||
| Q3 25 | 6.7% | 4.7% | ||
| Q2 25 | 8.1% | 7.2% | ||
| Q1 25 | 8.4% | 4.9% | ||
| Q4 24 | 11.2% | 5.0% | ||
| Q3 24 | 11.2% | 3.8% | ||
| Q2 24 | 6.6% | 2.6% |
现金转化率DXCMRBA
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 2.33× | ||
| Q3 25 | 2.33× | 2.51× | ||
| Q2 25 | 1.69× | 2.97× | ||
| Q1 25 | 1.74× | 1.38× | ||
| Q4 24 | 1.99× | 1.56× | ||
| Q3 24 | 1.48× | 3.75× | ||
| Q2 24 | 1.95× | 3.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DXCM
暂无分部数据
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
